Log In
BCIQ
Print this Print this
 

PRX002, RG7935

  Manage Alerts
Collapse Summary General Information
Company Prothena Corp. plc
Description mAb targeting alpha synuclein (SNCA)
Molecular Target Alpha synuclein (SNCA)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD)
Regulatory Designation
PartnerRoche

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$600.0M

0

$555.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/16/2013

$600.0M

Undisclosed

$555.0M

Get a free BioCentury trial today